Synthesis and biological evaluation of 1,1-dichloro-2,3-diarylcyclopropanes as antitubulin and anti-breast cancer agents

Bioorganic and Medicinal Chemistry

Volumn 5, Issue 4, 1997, Pages 715-722

  Jonnalagadda, Sastry S ^a,e   Ter Haar, Ernst ^a,f   Hamel, Ernest ^c   Lin, Chii M ^c   Magarian, Robert A ^d   Day, Billy W ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e Eurand Inc   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DICHLORO 2,3 DIPHENYLCYCLOPROPANE; ANTINEOPLASTIC AGENT; CYCLOPROPANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROTUBULE; MICROTUBULE ASSEMBLY;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BREAST NEOPLASMS; CARCINOMA; CATTLE; CELL CYCLE; CELL DIVISION; CHROMATOGRAPHY, LIQUID; COLCHICINE; CYCLOPROPANES; DIETHYLSTILBESTROL; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICROTUBULES; POLYMERS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS; RODENTIA;

EID: 0002453760     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(97)00014-X     Document Type: Article

References (17)

1. Magarian, R. A.; Benjamin, E. J. J. Pharm. Sci 1975, 64, 1626.
2. Pento, J. T.; Magarian, R. A.; Wright, R. J.; King, M. M.; Benjamin, E. J. J. Pharm. Sci. 1981, 70, 399.
3. Day, B. W.; Magarian, R. A.; Pento, J. T.; Jain, P. T.; Mousissian, G. K.; Meyer, K. L. J. Med. Chem. 1991, 34, 842.
4. Pento, J. T.; Magarian, R. A.; King, M. M. Cancer Lett. 1982, 15, 261.
5. King, M. M.; Pento, J. T.; Magarian, R. A.; Brueggemann, G. L. J. Natl. Cancer Inst. 1985, 74, 447.
6. Ter Haar, E.; Day, B. W. Anticancer Res. 1996, 16, 1107.
7. Ter Haar, E.; Hamel, E.; Balachandran, R.; Day, B. W. Anticancer Res., in press.
8. Magarian, R. A.; Avor K. S.; Overacre, L. B.; Kunchandy, J.; Paxton, T. R. Anti-Cancer Drug Design 1995, 10, 311.
9. Pento, J. T.; Koenig, K. K.; Magarian, R. A.; Kosanke, S. D.; Gilliland, D. L. J. Pharm. Sci. 1988, 77, 120.
10. Stobaugh, J. F.; Magarian, R. A.; Pento, J. T. J. Pharm. Sci. 1982. 71, 1126.
11. Afzal, J.; Magarian, R. A.; Griffin, M. T.; Pento, J. T. Syn. Commun. 1989, 19, 3061.
12. Griffin, M. T.; Magarian, R. A.; Jain, P.; Pento, J. T.; Mousissian, G. K.; Graves, D. C. Anti-Cancer Drug Design 1992, 7, 49.
13. Hamel, E; Lin, C. M. Biochemistry 1984, 23, 4173.
14. Blokhin, A. V.; Yoo, H.-D.; Geralds, R. S.; Nagle, D. E.; Gerwick, W. H.; Hamel. E. Mol. Pharmacol. 1995, 48, 523.
15. Ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longley, R. E.; Gunasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Biochemistry 1996, 35, 243.
16. Sakakibara, Y.; Saito, I.; Ichinoseki, K.; Oda, T.; Kaneko, M.; Saito, H.; Kodama, M.; Sato, Y. Mutation Res. 1991, 263, 269.
17. Sakakimara, Y.; Saito, I.; Oda, T.; Tsujibo, H.; Inamori, Y.; Sato, Y. Chem. Pharm. Bull. 1992, 40, 2115.